Clinical Trials Browser

Phase 2 × Recruiting × Central Nervous System Diseases × Clear all

NCT07326566 2026-03-19

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma